Association of Connexin 32 with Prostate Volume and PSA Level in Prostatic Adenocarcinoma and Adenomyomatous Hyperplasia

Objective: Prostate cancer (PC) is the second most common cancer in men in the world. PC is associated with many parameters. Connexins may also be prognostic parameters in this study, we aimed to evaluate Cx32 expression in prostatic adenocarcinomas (PCa) and adenomyomatous hyperplasia (AH). In addition, age, prostate-specific antigen (PSA) level, prostate volume (PV), Gleason score (GS) (and grade group) were also evaluated. Materials and Methods: This study was conducted on a total of 48 cases including 23 PCa and 25 AH. Prostate samples were stained with Cx32 antibody by immunohistochemical method. Age, GS (and grade group), PV and PSA values were recorded. Cx32 staining intensity of the cases were evaluated statistically with these parameters. Results: The age range of patients with PCa and AH was 46-83 years and 50-86 years, respectively. The PV in PCa patients and AH patients ranged from 21 to 135 mL and from 36 to 110 mL, respectively. The PSA value in PCa and AH patients ranged from 1 to 1122 ng/mL and from 1 to 16 ng/mL, respectively. In cases with PCa, no statistically significant correlation was observed between GS and age and intensity of CX32 staining (p=0.523 and p=0.093, respectively). However, the mean age of Cx32-positive patients was higher than that of Cx32-negative patients (72.62 vs 67.03). The rate of Cx32- positive PCa cases was higher than that of AH cases (39.1% vs 24%). Conclusion: Cx32 expression tended to increase with age. However, no significant relationship was found between PCa and AH and Cx32.

Prostat Adenokarsinomu ve Adenomyomatöz Hiperplazide Prostat Hacmi ve PSA Düzeyi ile Connexin 32 İlişkisi

Amaç: Prostat kanseri, dünyada erkeklerde en sık görülen ikinci kanserdir. Prostat kanseri birçok parametreyle ilişkilidir. Belki de konnexinler de prognostik parametre olabilirler. Bu çalışmada, prostat adenokarsinomu (PCa) ve adenomyomatöz hiperplazide (AH) Cx32 ekspresyonunu değerlendirmeyi amaçladık. Ayrıca yaş, prostat spesifik antijen (PSA) düzeyi, prostat hacmi (PV), Gleason skoru (GS) (ve grade grubu) da değerlendirildi. Gereç ve Yöntem: Bu çalışma 23 PCa ve 25 AH dahil toplam 48 olgu üzerinde gerçekleştirildi. Prostat örnekleri immünohistokimyasal yöntemle Cx32 antikoru ile boyandı. Yaş, GS, PV ve PSA değerleri kaydedildi. Olguların Cx32 boyama şiddeti bu parametrelerle istatistiksel olarak değerlendirildi. Bulgular: PCa ve AH hastalarının yaş aralığı sırasıyla 46-83 ve 50-86 idi. PCa hastalarında ve AH hastalarında PV sırasıyla 21 ila 135 mL ve 36 ila 110 mL arasında değişmekteydi. PCa ve AH hastalarındaki PSA değeri sırasıyla 1 ila 1122 ng/mL ve 1 ila 16 ng/mL arasında değişmekteydi. PCa olgularında Cx32 boyama şiddetinin GS ve yaş arasında istatistiksel olarak anlamlı bir ilişki gözlenmemiştir (sırasıyla p=0,523 ve p=0,093). Bununla birlikte, Cx32 pozitif olguların ortalama yaşı, Cx32 negatif olguların yaşından daha yüksekti (72,62 vs 67,03). Yüzde olarak, Cx32 pozitif PCa olgu sayısı AH olgu sayısından daha yüksekti (%39,1/%24). Sonuç: Cx32 ekspresyonu yaşla birlikte artma eğilimindedir. Bununla birlikte, PCa ile AH ve Cx32 arasında anlamlı bir ilişki bulunamadı.

Kaynakça

Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24::2137-2150.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.

Hong R, Lim SC. Pathological significance of connexin 26 expression in colorectal adenocarcinoma. Oncology Reports 2008;19:913-919.

Aslan Y, Tekdogan U, Tuncel A, Uzun MB, Karabulut E, Atan A. Serum dehydroepiandrosterone sulfate usage for early detection of prostate cancer in men with serum prostate specific antigen level between 2.5 and 4.0 ng/mL: a pilot study. Turk J Med Sci 2008;38:399-404.

Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-1161.

Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-1242.

D’Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen M, Art M, Tomaszewski JE, Wein A. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 2000;55:572-577.

Tsivian M, Sun L, Mouraviev V, Madden JF, Mayes JM, Moul JW, Polascik TJ. Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. Urology 2009;74:1090-1093.

Budäus L, Isbarn H, Eichelberg C, Lughezzani G, Sun M, Perrotte P, Chun FK, Salomon G, Steuber T, Köllermann J, Sauter G, Ahyai SA, Zacharias M, Fisch M, Schlomm T, Haese A, Heinzer H, Huland H, Montorsi F, Graefen M, Karakiewicz PI. Biochemical recurrence after radical prostatectomy: multiplicative interaction between surgical margin status and pathological stage. J Urol 2010;184:1341-1346.

Yen MR, Saier MH Jr. Gap junctional proteins of animals: the innexin/ pannexin superfamily. Prog Biophys Mol Biol 2007;94:5-14.

Willecke K, Eiberger J, Degen J, Eckardt D, Romualdi A, Güldenagel M, Deutsch U, Söhl G. Structural and functional diversity of connexin genes in the mouse and human genome. Biol Chem 2002;383:725-737.

Scemes E, Spray DC, Meda P. Connexins, pannexins, innexins: novel roles of “hemi-channels”. Pflugers Arch 2009;457:1207-1226.

Beyer EC, Paul DL, Goodenough DA. Connexin43: A protein from rat heart homologous to a gap junction protein from liver. J Cell Biol 1987;105:2621- 2629.

Hervé JC, Derangeon M, Sarrouilhe D, Giepmans BN, Bourmeyster N. Gap junctional channels are parts of multiprotein complexes. Biochim Biophys Acta 2012;1818:1844-1865.

Eiberger J, Degen J, Romualdi A, Deutsch U, Willecke K, Söhl G. Connexin genes in the mouse and human genome. Cell Commun Adhes 2001;8:163- 165.

Bosco D, Haefliger JA, Meda P. Connexins: key mediators of endocrine function. Physiol Rev 2011;91:1393-1445.

Poyet C, Buser L, Roudnicky F, Detmar M, Hermanns T, Mannhard D, Höhn A, Rüschoff J, Zhong Q, Sulser T, Moch H, Wild PJ. Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer. Journal of Clinical Pathology 2015;68:819-824.

Saraon P, Jarvi K, Diamandis EP. Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem 2011;57:1366-1375.

Deng FM, Donin NM, Pe Benito R, Melamed J, Le Nobin J, Zhou M, Ma S, Wang J, Lepor H. Size-adjusted Quantitative Gleason Score as a Predictor of Biochemical Recurrence after Radical Prostatectomy. Eur Urol 2016;70:248-253.

Bai PD, Hu MB, Xu H, Zhu WH, Hu JM, Yang T, Jiang HW, Ding Q. Body mass index is associated with higher Gleason score and biochemical recurrence risk following radical prostatectomy in Chinese men: a retrospective cohort study and meta-analysis. World J Surg Oncol 2015;13:311.

Kang HW, Jung HD, Lee JY, Kwon JK, Jeh SU, Cho KS, Ham WS, Choi YD. Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer. Asian J Androl 2016;18:480-484.

Ma HQ, Liang XT, Zhao JJ, Wang H, Sun JC, Chen YB, Pan K, Xia JC. Decreased expression of Neurensin-2 correlates with poor prognosis in hepatocellular carcinoma. World journal of gastroenterology 2009;15:4844-4848.

Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 2010;58:831-835.

Jee H, Nam KT, Kwon HJ, Han SU, Kim DY. Altered expression and localization of connexin 32 in human and murine gastric carcinogenesis. Dig Dis Sci 2011;56:1323-1332.

Fujimoto E, Sato H, Shirai S, Nagashima Y, Fukumoto K, Hagiwara H, Negishi E, Ueno K, Omori Y, Yamasaki H, Hagiwara K, Yano T. Connexin-32 as a tumor suppressor gene in a metastatic renal cell carcinoma cell line. Oncogene 2005;24:3684-3690.

Xu N, Chen HJ, Chen SH, Xue XY, Chen H, Zheng QS, Wei Y, Li XD, Huang JB, Cai H, Sun XL. Reduced Connexin 43 expression is associated with tumor malignant behaviors and biochemical recurrence-free survival of prostate cancer. Oncotarget 2016;7:67476-67484.

Saladino F, Carruba G, Quader ST, Amoroso M, Di Cristina A, Webber M, Castagnetta LA. Connexin expression in nonneoplastic human prostate epithelial cells. Ann N Y Acad Sci 2002;963:213-217.

Hu LP, Liu ZX, Bai ZM, Tan S. Expressions of Cx26, Cx32 and Cx43 in prostate cancer and their implications. Zhonghua Nan Ke Xue 2014;20:23-29.

Mochtar CA, Kiemeney LA, van Riemsdijk MM, Barnett GS, Laguna MP, Debruyne FM, de la Rosette JJ. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 2003;44:695-700.

Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M, Schnorr D, Loening SA, Jung K. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of <4 ng/mL. Cancer 2005;104:993- 1003.

Carter HB, Partin AW. Diagnosis and staging of prostate cancer. Chapter 88. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Campbell’s Urology. 8th edition, Philiadelphia: Saunders; 2002, pp 3055-3079.

Hussein S, Satturwar S, Van der Kwast T. Young-age prostate cancer. J Clin Pathol 2015;68:511-515.

Kaynak Göster

494 167

Arşiv
Sayıdaki Diğer Makaleler

Comparison of 99mTc-DMSA, 99mTc-DTPA and 99mTc-MAG3 Renal Scintigraphy in the Calculation of Relative Renal Function

Fadime DEMİR, Mustafa DEMİR

Is Bacterial Colonization in Ureteral Double-J Stents Significant and Is It Predictable?

Ahmet ŞAHAN, Alkan ÇUBUK, Kasım ERTAŞ, Asgar GARAYEV, Ferhat TALİBZADE, Çağrı Akın ŞEKERCİ, Tuncay TOPRAK, YILÖREN TANIDIR

Evaluation of Treatment Applications and Antibiotic Resistance Rates for Community Acquired Urinary Tract Infections in Turkey and a Review of the Literature

Aşkın EROĞLU, Elçin AKDUMAN ALAŞEHİR

Association of Connexin 32 with Prostate Volume and PSA Level in Prostatic Adenocarcinoma and Adenomyomatous Hyperplasia

HAVVA ERDEM, Abdullah ÇIRAKOĞLU, Erdal BENLİ, Soner ÇANKAYA

Laparoscopic Pyeloplasty, Our Experience of Initial Fifty Two Cases

Lokesh SHARMA, Nisar AHMED, Mahakshit BHAT, Aayush KHETRAPAL, Rajeev MATHUR, Ram Gopal YADAV

Hydrocele Rupture during Sexual Intercourse: a Case Report and Review of the Literature

Deniz BOLAT, Anıl EKER, Hamza Eren GÜZEL, Tansu DEĞİRMENCİ

Granular Cell Tumors of the Urinary Bladder: An Extremely Rare Entity and Literature Review

İsmail EVREN, Osman ÖZDEMİR, Yunus ÇOLAKOĞLU, Nurten SEVER, Ali İhsan TAŞÇI

A Rare Case of Incidentally Detected Fused Supernumerary Kidney

Elif GÜNDOĞDU, Emre EMEKLİ

Risk Factors for Postoperative Urinary Retention in Surgical Population: A Prospective Cohort Study

Meltem ÇAKMAK, Murside YILDIZ, İlker AKARKEN, Yücel KARAMAN, Özgür ÇAKMAK

Significance of Core Length in Current Transrectal Ultrasound-guided Prostate Biopsy in Patients with Normal Digital Rectal Examination

Mesut ALTAN, Burak ÇITAMAK, Emin MAMMADOV, NAİME MERİÇ KONAR, Bülent AKDOĞAN, Haluk ÖZEN